Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia

Model scores of the 29,894 trials active now.

Model score 24% for any early termination, 9% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2021-01-20. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: chemotherapypatientpriorleukemiaacute
  Phrases that lowered it: investigatorpatients whodrugspatients withmale
• Sponsor's past termination rate: 27.7% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Trials the sponsor started in the prior 2 years: 172 (lowers risk) · Sponsor's track record
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 15.8% (lowers risk) · Drug's FDA history
• Drug's FAERS reports before start: 572549 (lowers risk) · Drug's FDA history
• Design: sequential (raises risk) · Design
• Number of arms: 3 (lowers risk) · Design
• Drug's FAERS reports marked serious: 76.6% (lowers risk) · Drug's FDA history
• Drugs with FDA adverse-event history: 17 (raises risk) · Drug's FDA history
• Drug's FAERS reports in the prior 12 months: 114722 (lowers risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Has a data monitoring committee: No (lowers risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Sponsor's past trials: 542 (lowers risk) · Sponsor's track record
• Responsible party: sponsor (lowers risk) · Design
• Blinding: none (raises risk) · Design
• Collaborators: 1 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia NCT04752163 · started 2021 · scored riskier than 94% of active trials terminated
• Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia NCT04915612 · started 2021 · scored riskier than 78% of active trials completed
• Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML NCT02311998 · started 2015 · scored riskier than 84% of active trials completed
• Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms NCT03878199 · started 2019 · scored riskier than 83% of active trials terminated
• INCB018424 in Patients With Advanced Hematologic Malignancies NCT00674479 · started 2008 · scored riskier than 99% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.